草酸艾司西酞普兰治疗慢性阻塞性肺疾病合并焦虑抑郁的临床疗效及对患者C-反应蛋白与肺功能指标的影响  

Clinical efficacy of escitalopram oxalate in the treatment of chronic obstructive pulmonary disease complicated with anxiety and depression and its influence on C-reactive protein and pulmonary function index in patients

作　　者：赖慧国 钟凤元 王磊 钟林海 LAI Huiguo;ZHONg Fengyuan;WANG Lei;ZHONG Linhai(The Third People's Hospital of Ganzhou City,Ganzhou,Jiangxi,341000,China)

机构地区：[1]赣州市第三人民医院,江西赣州341000

出　　处：《当代医学》2023年第31期18-21,共4页Contemporary Medicine

基　　金：赣州市2021年指导性科技计划项目(GZ2021ZSF233)。

摘　　要：目的探究草酸艾司西酞普兰治疗慢性阻塞性肺疾病(COPD)合并焦虑抑郁的临床疗效及对患者C-反应蛋白(CRP)与肺功能的影响。方法选取2020年8月至2021年4月赣州市第三人民医院门诊及住院合并焦虑抑郁的60例COPD患者作为研究对象,按照随机数字表法分为实验组与对照组,每组30例。对照组采用COPD规范化治疗,实验组在对照组治疗基础上联合草酸艾司西酞普兰治疗。比较两组治疗前后汉密尔顿抑郁量表(HAMD)评分、汉密顿焦虑量表(HAMA)评分、C-反应蛋白(CRP)水平、肺功能指标[第1秒用力呼气容积/用力肺活量(FEV1/FVC)、FEV1占预计值百分比(FEV1%Pre)]、COPD患者自我评估测试(CAT)评分及呼吸困难程度。结果治疗后,两组HAMD、HA-MA、CAT评分及CRP水平均低于治疗前,且实验组低于对照组,差异有统计学意义(P<0.05);治疗后,两组FEV1/FVC、FEV1%Pre均高于治疗前,且实验组高于对照组,差异有统计学意义(P<0.05);实验组改良英国MRC呼吸困难指数分级表(mMRC)分级优于对照组,差异有统计学意义(P<0.05)。结论草酸艾司西酞普兰联合常规COPD治疗能有效改善合并焦虑抑郁COPD患者焦虑、抑郁症状,降低CRP水平,改善肺功能和COPD症状,值得临床推广应用。Objective To investigate the clinical efficacy of escitalopram oxalate in the treatment of chronic obstructive pulmonary disease(COPD)complicated with anxiety and depression and its influence on C-reactive protein(CRP)and pulmonary function index in patients.Methods 60 COPD patients comorbid anxiety and depression with outpatient and inpatient in the Third People's Hospital of Ganzhou City from August 2020 to April 2021 were selected as the study subjects,and they were divided into the experimental group and the control group according to the random num-ber table method,with 30 cases in each group.The control group was treated with standardised COPD treatment,and the experimental group was combined with escitalopram oxalate on the basis of control group treatment.The Hamilton depression scale(HAMD)scores,Hamilton anxiety scale(HAMA)scores,C-reactive protein(CRP)level,pulmonary function index(forced expiratory volume in one second/forced vital capacity[FEV1/FVC],forced expiratory volume in one second/predict[FEV1%Pre]),chronic obstructive pulmoriary disease assessment test(CAT)score before and after treatment and degree of dyspnea were compared between the two groups.Results After treatment,HAMD,HAMA,CAT scores and CRP lev-els of the two groups were lower than before treatment,and the experimental group was lower than the control group,and the differences were statis-tically significant(P<0.05).After treatment,FEV1/FVC and FEV1%Pre of the two groups were higher than before treatment,and the experimental group was higher than the control group,the differences were statistically significant(P<0.05).The modified British medicalresearch council(mMRC)classification in the experimental group was better than that in the control group,and the difference was statistically significant(P<0.05).Conclusion Escitalopram oxalate combined with conventional COPD treatment can effectively improve anxiety and depression symptoms,reduce CRP levels,improve lung function and COPD symptoms in COPD patients with comorbid anxiety and depr

关 键 词：草酸艾司西酞普兰 焦虑 抑郁 慢性阻塞性肺疾病 

分 类 号：R563[医药卫生—呼吸系统]